Literature DB >> 2440391

A comparison between 25% albumin and 6% hydroxyethyl starch solutions on lung water accumulation during and immediately after cardiopulmonary bypass.

P D Lumb.   

Abstract

Six per cent hydroxyethyl starch was compared prospectively with 25% albumin as the oncotic component of cardiopulmonary pump prime solutions. Oncotic pressure of the pump prime solution was measured, and serum oncotic pressure (OP) values were recorded at designated times during the perioperative period. Changes in these values were compared with alterations in extravascular lung water (EVLW), the serum oncotic pressure-pulmonary artery occluded pressure gradient and the alveolar-arterial difference in oxygen tension [D(A-a)O2] before and immediately after bypass and in the surgical intensive care unit after operation. A significant increase in EVLW was associated with a decrease in serum OP and an increase in D(A-a)O2 immediately after bypass. However, EVLW values had returned to baseline by time of determination in the surgical intensive care unit. Cost savings may be realized by the use of hydroxyethyl starch in this setting if average wholesale price data are representative of costs throughout the country.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 2440391      PMCID: PMC1493097          DOI: 10.1097/00000658-198708000-00015

Source DB:  PubMed          Journal:  Ann Surg        ISSN: 0003-4932            Impact factor:   12.969


  18 in total

1.  CIRCULATORY RESPONSES TO INTRAVENOUS INFUSIONS OF HYDROXYETHYL STARCH SOLUTIONS.

Authors:  W L THOMPSON; R P WALTON
Journal:  J Pharmacol Exp Ther       Date:  1964-12       Impact factor: 4.030

2.  Bedside measurement of lung water.

Authors:  F R Lewis; V B Elings; J A Sturm
Journal:  J Surg Res       Date:  1979-10       Impact factor: 2.192

3.  Routine plasma colloid osmotic pressure measurements.

Authors:  M H Weil; M Morissette; S Michaels; J Bisera; E Boycks; H Shubin; E Jacobson
Journal:  Crit Care Med       Date:  1974 Sep-Oct       Impact factor: 7.598

4.  Albumin and water fluxes during cardiopulmonary bypass.

Authors:  H W Beattie; G Evans; E S Garnett; E Regoeczi; C E Webber; K L Wong
Journal:  J Thorac Cardiovasc Surg       Date:  1974-06       Impact factor: 5.209

5.  Clinical evaluation of a new plasma expander hydroxyethyl starch.

Authors:  W H Lee; N Cooper; M G Weidner; E S Murner
Journal:  J Trauma       Date:  1968-05

6.  Extravascular lung water accumulation in patients following coronary artery surgery.

Authors:  R J Byrick; C Kay; W H Noble
Journal:  Can Anaesth Soc J       Date:  1977-05

7.  Fulminating noncardiogenic pulmonary edema. A newly recognized hazard during cardiac operations.

Authors:  A T Culliford; S Thomas; F C Spencer
Journal:  J Thorac Cardiovasc Surg       Date:  1980-12       Impact factor: 5.209

8.  Complement activation during cardiopulmonary bypass: evidence for generation of C3a and C5a anaphylatoxins.

Authors:  D E Chenoweth; S W Cooper; T E Hugli; R W Stewart; E H Blackstone; J W Kirklin
Journal:  N Engl J Med       Date:  1981-02-26       Impact factor: 91.245

9.  Hydroxyethyl starch for resuscitation of patients with hypovolemia and shock.

Authors:  V K Puri; B Paidipaty; L White
Journal:  Crit Care Med       Date:  1981-12       Impact factor: 7.598

10.  Hemodynamic, blood volume, and oxygen transport responses to albumin and hydroxyethyl starch infusions in critically ill postoperative patients.

Authors:  S Lazrove; K Waxman; C Shippy; W C Shoemaker
Journal:  Crit Care Med       Date:  1980-05       Impact factor: 7.598

View more
  2 in total

Review 1.  Hydroxyethyl starch for cardiovascular surgery: a systematic review of randomized controlled trials.

Authors:  Xue-Yin Shi; Zui Zou; Xing-Ying He; Hai-Tao Xu; Hong-Bin Yuan; Hu Liu
Journal:  Eur J Clin Pharmacol       Date:  2011-03-02       Impact factor: 2.953

2.  Update on transfusion solutions during surgery: review of hydroxyethyl starches 130/0.4.

Authors:  Ornella Piazza; Giuliana Scarpati; Rosalba Tufano
Journal:  Int J Gen Med       Date:  2010-10-05
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.